恩威医药
(301331)
| 流通市值：32.81亿 | | | 总市值：32.87亿 |
| 流通股本：1.03亿 | | | 总股本：1.03亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 449,221,452.75 | 196,499,491.35 | 812,127,431.13 | 560,341,100.4 |
| 营业收入 | 449,221,452.75 | 196,499,491.35 | 812,127,431.13 | 560,341,100.4 |
| 二、营业总成本 | 408,252,811.68 | 183,733,734.69 | 763,172,474.47 | 534,869,746.2 |
| 营业成本 | 228,665,720.71 | 101,928,907.9 | 399,443,939.66 | 274,836,889.56 |
| 税金及附加 | 5,351,510.43 | 2,056,668.59 | 12,555,058.15 | 9,447,037.16 |
| 销售费用 | 136,750,988.16 | 60,842,025.31 | 267,145,001.09 | 187,705,109.1 |
| 管理费用 | 34,640,236.72 | 17,722,947.71 | 76,226,203.19 | 58,126,682.55 |
| 研发费用 | 2,538,865.32 | 1,085,549.14 | 9,073,915.83 | 5,770,697.03 |
| 财务费用 | 305,490.34 | 97,636.04 | -1,271,643.45 | -1,016,669.2 |
| 其中:利息费用 | 1,645,288.24 | 828,750 | 2,426,424.62 | 1,476,158.26 |
| 其中:利息收入 | 1,448,947.99 | 791,658.07 | 4,090,693.9 | 2,831,648.23 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 2,818,800.74 | 1,132,468.42 | 3,494,421.27 | 2,400,428.63 |
| 资产处置收益 | -263,274.66 | - | -263,488.07 | -166,771.5 |
| 资产减值损失(新) | 1,948,506.26 | 2,643,099.55 | -3,877,937 | -1,225,604.44 |
| 信用减值损失(新) | -1,278,804.58 | 601,274.29 | -1,506,376.82 | -511,935.99 |
| 其他收益 | 1,707,535.87 | 1,053,346.16 | 2,884,939.95 | 2,565,868.93 |
| 四、营业利润 | 45,901,404.7 | 18,195,945.08 | 49,686,515.99 | 28,533,339.83 |
| 加:营业外收入 | 41,133.13 | 1,506.8 | 223,998.78 | 211,685.68 |
| 减:营业外支出 | 213,098.44 | 210,812.14 | 3,226,680.45 | 3,222,443.46 |
| 五、利润总额 | 45,729,439.39 | 17,986,639.74 | 46,683,834.32 | 25,522,582.05 |
| 减:所得税费用 | 7,385,258.14 | 1,681,512.85 | 9,186,289.97 | 3,500,619.47 |
| 六、净利润 | 38,344,181.25 | 16,305,126.89 | 37,497,544.35 | 22,021,962.58 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 38,344,181.25 | 16,305,126.89 | 37,497,544.35 | 22,021,962.58 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 38,344,181.25 | 16,305,126.89 | 37,497,544.35 | 22,021,962.58 |
| 扣除非经常损益后的净利润 | 35,275,716.98 | 14,624,801.81 | 34,729,637.24 | 20,443,049.91 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.38 | 0.16 | 0.37 | 0.22 |
| (二)稀释每股收益 | 0.38 | 0.16 | 0.37 | 0.22 |
| 九、综合收益总额 | 38,344,181.25 | 16,305,126.89 | 37,497,544.35 | 22,021,962.58 |
| 归属于母公司股东的综合收益总额 | 38,344,181.25 | 16,305,126.89 | 37,497,544.35 | 22,021,962.58 |
| 公告日期 | 2025-08-26 | 2025-04-21 | 2025-04-21 | 2024-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |